AI Medical Service is an artificial intelligence and healthcare company making software for the early detection of gastrointestinal cancers that is headquartered in Toshima, Tokyo and was founded in 2017 by Tomohiro Tada. The company's software analyzes endoscope images to support endoscopists and help doctors make diagnoses.
On August 10, 2018 AI Medical Service announced raising ¥1 billion in series A funding from Incubate Fund.
On October 4, 2019 AI Medical Service announced raising ¥4.6 billion ($42.9 million USD) in series B funding from WiL (lead investor), Sony Innovation Fund (lead investor), Globis Capital Partners (lead investor), SPARX Group, SMBC Venture Capital, Ryoyo Electro Corporation, Japan Post Capital, Innovation Growth Ventures, and Daiwa Corporate Investment. The company plans on using their series B funding to fund clinical trials for its early detection software. The director of Globis Capital, Satoshi Fukushima, made the following statement about AI Medical Service after participating in the company's series B funding round:
We foresee an irreversible trend of doctors diagnosing cancer in collaboration with AI in the near future. Supported by the world’s leading medical institutions and specialists in the field and led by experienced management, the endoscopy AI developed by AIM has huge potential to help endoscopists and patients globally.